Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Caterpillar Inc (CAT) vs 10X Genomics Inc (TXG) Price & Performance

Caterpillar IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Caterpillar Inc vs 10X Genomics Inc — how do they compare? Caterpillar Inc trades at $939.95 (market cap $429.89B), while 10X Genomics Inc trades at $45.99 (market cap $5.81B). The key difference: Caterpillar Inc is far larger — about 74× 10X Genomics Inc's market cap, and Caterpillar Inc pays a 0.7% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

CATTXG
Market Cap
$429.89B$5.81B
Sector
IndustrialsHealth
52-Week High
$1.06K$45.80
52-Week Low
$404.64$11.34
Enterprise Value
$468.88B$5.36B
Dividend Yield
0.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Caterpillar Inc

Caterpillar (CAT) trades at $933.34, down 2.0% on the day but up 51% year-to-date, reflecting strong momentum from AI-driven infrastructure demand. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $5.54 surpassing expectations by 19%. Valuation metrics remain elevated with a P/E of 46.39 and P/S of 6.18, while profitability remains robust with a 13.33% net margin and 51.35% ROE. Technical indicators show neutral signals with support at $922 and resistance at $943.

Outlook remains positive with analyst consensus pointing to $1,020 price target (9% upside) and 55% buy ratings. Key opportunities include AI data center power demand generating $10.2B in generator sales, while risks include elevated valuation and cyclical exposure to economic conditions. The company's 32nd consecutive dividend increase expected in June supports income investors.

10X Genomics Inc

TXG trades at $41.77, down 2.25% today, with a bullish technical setup supported by moving averages. The company shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while recent collaborations with Cleveland Clinic and the Proteintech acquisition expand its diagnostic capabilities. Analyst sentiment is mixed with 45% buy ratings but a consensus price target below current levels.

The outlook suggests cautious optimism as TXG demonstrates operational improvement with positive cash flow generation, though profitability remains elusive. Key risks include execution challenges in new ventures and competitive pressures, while upside potential hinges on continued margin expansion and successful integration of recent acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Caterpillar Inc

Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.

Read more on CAT

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG